Elizabeth Gardner

Treating older patients with breast cancer must include more quality of life considerations and different types of survival calculations.

The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status.

Patients have a hard time with artificially induced menopause and some research suggests it may have a negligible effect on the success of their treatment.

Multigene panel testing offers a new but often puzzling tool for breast cancer treatment, since the results are often difficult to interpret, both for relative risk and risk management.

Even with advancements in technology, the prospect of artificial intelligence treating patients with cancer still remains out of reach. At least, for now.

Extra vigilance, careful management, and an emphasis on empathy makes treating cancer pain more effective during an opioid addiction epidemic.

The keynote address at the 2015 LUGPA Annual Meeting urged physicians to band together and create an offensive strategy when it comes to the nation's healthcare system.

Hormone therapies for prostate cancer aimed at reducing serum androgens are trained on the wrong target: the testes and the adrenal glands. Rather, they should attack the prostate cancer cells themselves.

E. David Crawford, MD, discussed issues with FDA standards for ADT agents and current treatment approaches to androgen deprivation in prostate cancer at the 2015 LUGPA Annual Meeting.